Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization ReadinessAccesswire · Oct 13, 2026
Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis PatientsBenzinga · Oct 6, 2026
Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic ShockAccesswire · Oct 6, 2026
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare MarketsGlobeNewsWire · Sep 8, 2026
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and CommercializationGlobeNewsWire · Aug 13, 2026Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$3,520.00 | -$1.12 | Beat |
| May 13, 2026 | – | -$1.95 | |
| Mar 6, 2026 | – | -$2.37 | |
| Nov 7, 2025 | – | -$4.04 | |
| Aug 7, 2025 | -$144.00 | -$5.64 | Beat |
| May 13, 2025 | -$1,152.00 | -$13.48 | Beat |